Cancer Cell Biology The goal of the Cancer Cell Biology Program is to foster integrated research that spans key themes of modern cell biology, especially as they relate to cancer etiology, prevenfion and therapy, to enhance the capabilities of members through establishment or expansion of appropriate core facilities, and to promote interactions with other UNC LCCC basic, clinical and population science programs. Program research is organized around five major areas: angiogenesis & vascular biology, cell adhesion & cytoskeleton, cell cycle, cell signaling, and chromatin regulation & epigenetics. Program highlights include the discoveries: by Yi Zhang (appointed as an Investigator of Howard Hughes Medical Institute, 2004) of the JmjC domain (JMJD) family of histone demethylases and the function of demethylase D0T1L in in leukemogenesis {Cell, 2005); by Ted Salmon (elected a member of the American Academy of Arts and Sciences, 2006) of the control and architecture of the kinetochore {Cell, 2005; Cell, 2007; Cell, 2009); by Jim Bear (appointed as Early Career Scientist by the Howard Hughes Medical Institute, 2009) of new mechanism in the control of actin architecture branching; by Henrik Dohlman of new RGS pathway components; by Bill Marzluff the key components of histone pre-mRNA processing; and by Yue Xiong of the mechanism underlying glioma-mutation of metabolic enzyme 1DH1 and acetylation of metabolic enzymes by acetylation. The Program is led by Dr. Yue Xiong, professor of Biochemistry & Biophysics, a Program member since 1993 and Leader since 2006. He is known for his studies of cell cycle control, tumor suppression and the ubiquitin pathway. At present, the Program has 47 members who have generated a total of $35.1 M (total cost) in extramural funding in 2009, including $6.1 million of NCI funding. From 2004 to 2009, the total number of publications was 1,245; 10% of which were intra-programmatic and 10% were inter-programmatic. Future plans for the Program include selective recruitment in new areas, and increased emphasis on translational studies and intra- and inter-programmatic interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-39
Application #
8786506
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
39
Fiscal Year
2015
Total Cost
$173,149
Indirect Cost
$73,407
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447

Showing the most recent 10 out of 1525 publications